239
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Identification of rare high-risk copy number variants affecting the dopamine transporter gene in mental disorders

, , , , , , , , , & show all
Pages 276-279 | Received 19 Jun 2015, Accepted 14 Sep 2015, Published online: 11 Nov 2015
 

Abstract

Background: The dopamine transporter, also known as solute carrier 6A3 (SLC6A3), plays an important role in synaptic transmission by regulating the reuptake of dopamine in the synapses. In line with this, variations in the gene encoding this transporter have been linked to both schizophrenia and affective disorders. Recently, copy number variants (CNVs) in SLC6A3 have been identified in healthy subjects but so far, the implication of CNVs affecting this gene in psychiatric diseases has not been addressed. Aims: In the present study, we aimed to investigate whether CNVs affecting SLC6A3 represent rare high-risk variants of psychiatric disorders. Methods: We performed a systematic screening for CNVs affecting SLC6A3 in 761 healthy controls, 672 schizophrenia patients, and 194 patients with bipolar disorder in addition to 253 family members from six large pedigrees affected by mental disorders using single nucleotide polymorphism arrays and subsequent verification by real-time polymerase chain reaction. Results: We identified two duplications and one deletion affecting SLC6A3 in the patients, while no such CNVs were identified in any of the controls. The identified CNVs were of different sizes and two affected several genes in addition to SLC6A3. Conclusion: Our findings suggest that rare high-risk CNVs affecting the gene encoding the dopamine transporter contribute to the pathogenesis of schizophrenia and affective disorders.

Acknowledgements

Louise K. Hoeffding and Linh T.T. Duong share authorship and have contributed equally to this work. Gerda Demant Olsen and Lisbeth Nymark Jørgensen are acknowledged for their technical assistance.

Disclosure of interest

L.T.T.D. has received a travelling grant from AstraZeneca, Denmark. T.W. has served as a lecturer for and consultant to H. Lundbeck. All other authors declare that they have no conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.